TEVETEN Drug Patent Profile

When do Teveten patents expire, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for TEVETEN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	3
Patent Applications:	4,172
Formulation / Manufacturing:	see details
DailyMed Link:	TEVETEN at DailyMed

Recent Clinical Trials for TEVETEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Quintiles, Inc.	Phase 3
Abbott	Phase 3
author! et al. BV	Phase 3

See all TEVETEN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TEVETEN

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for TEVETEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEVETEN	Tablets	eprosartan mesylate	400 mg and 600 mg	020738	1	2010-05-10

US Patents and Regulatory Information for TEVETEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997		DISCN	No	No
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-001	Nov 1, 2001		DISCN	No	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997		DISCN	Yes	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999		DISCN	Yes	No

Expired US Patents for TEVETEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997

International Patents for TEVETEN

See the table below for patents covering TEVETEN around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	2232	Imidazolyl-alkenoic acids
Luxembourg	90562
Hungary	903846
New Zealand	233996	IMIDAZOLYL-ALKENOIC ACID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

Supplementary Protection Certificates for TEVETEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0403159	C300006	Netherlands		PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417
0565634	300115	Netherlands
0565634	91234	Luxembourg		91234, EXPIRES: 20161213
0403159	SPC/GB00/010	United Kingdom		PRODUCT NAME: EPROSARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING EPROSARTAN MESYLATE; REGISTERED: DE 39 573.00.00 19970417; DE 39 573.01.00 19970417; DE 39 573.02.00 19970417; UK PL00512/0162 19990823; UK PL00512/0163 19990823; UK PL00512/0164 19990823